
    
      The primary objective of this trial is to explore the maximum tolerated dose(MTD),
      dose-limiting toxicity(DLT) of ALTN and rational dosage regimen for phase II study, to
      investigate the pharmacokinetics with single and multiple doses of ALTN from
      5mg/d,10mg/d,16mg/d,12mg.
    
  